Literature DB >> 23291318

Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target.

Mohammad Shahidul Makki1, E Cristy Ruteshouser, Vicki Huff.   

Abstract

Wilms tumor gene WT1 encodes a zinc finger-containing transcription factor which is required for renal development. Mutations in WT1 are observed in 20% of Wilms tumors (a pediatric kidney cancer), but the in vivo WT1 targets and associated molecular pathways involved in the etiology of Wilms tumor are still elusive. To identify WT1 targets we performed genome-wide comprehensive expression profiling using Affymetrix Gene Chip Mouse Genome 430 2.0 Arrays, comparing E13.5 mouse kidneys in which Wt1 had been somatically ablated with littermate controls. We identified Usp18 as the most differentially expressed gene in mutant kidney. Using tetracycline inducible cells we demonstrated a repressive effect of WT1 on USP18 expression. Conversely, knockdown of WT1 led to the upregulation of Usp18. Furthermore, direct binding of WT1 to the Usp18 promoter was demonstrated by ChIP assay. Overexpression of USP18 in murine and human cell lines resulted in cell proliferation. Additionally, Usp18 upregulation was observed in a mouse model of Wilms tumor. Taken together our data demonstrate that Usp18 is a transcriptional target of WT1 and suggest that increased expression of USP18 following WT1 loss contributes to Wilms tumorigenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291318      PMCID: PMC3791519          DOI: 10.1016/j.yexcr.2012.12.021

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  28 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Dysregulation of protein modification by ISG15 results in brain cell injury.

Authors:  Kenneth J Ritchie; Michael P Malakhov; Christopher J Hetherington; Liming Zhou; Marie-Terese Little; Oxana A Malakhova; Jack C Sipe; Stuart H Orkin; Dong-Er Zhang
Journal:  Genes Dev       Date:  2002-09-01       Impact factor: 11.361

3.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence.

Authors:  F J Rauscher; J F Morris; O E Tournay; D M Cook; T Curran
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

4.  Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.

Authors:  Qianghua Hu; Fei Gao; Weihua Tian; E Cristy Ruteshouser; Yaqing Wang; Alexander Lazar; John Stewart; Louise C Strong; Richard R Behringer; Vicki Huff
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

5.  Protein ISGylation modulates the JAK-STAT signaling pathway.

Authors:  Oxana A Malakhova; Ming Yan; Michael P Malakhov; Youzhong Yuan; Kenneth J Ritchie; Keun Il Kim; Luke F Peterson; Ke Shuai; Dong-Er Zhang
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

6.  The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains.

Authors:  Z Y Wang; Q Q Qiu; T F Deuel
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

7.  Transcriptional repression mediated by the WT1 Wilms tumor gene product.

Authors:  S L Madden; D M Cook; J F Morris; A Gashler; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

8.  Alternative splicing and genomic structure of the Wilms tumor gene WT1.

Authors:  D A Haber; R L Sohn; A J Buckler; J Pelletier; K M Call; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

9.  A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1.

Authors:  Z Y Wang; Q Q Qiu; K T Enger; T F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 10.  The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.

Authors:  Eric K Rowinsky
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

View more
  14 in total

1.  The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Authors:  S Agarwal; J U Kazi; S Mohlin; S Påhlman; L Rönnstrand
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

2.  MicroRNA-9 promotion of interleukin-6 expression by inhibiting monocyte chemoattractant protein-induced protein 1 expression in interleukin-1β-stimulated human chondrocytes.

Authors:  Mohammad S Makki; Abdul Haseeb; Tariq M Haqqi
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

Review 3.  Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.

Authors:  Lisa Maria Mustachio; Yun Lu; Masanori Kawakami; Jason Roszik; Sarah J Freemantle; Xi Liu; Ethan Dmitrovsky
Journal:  Cancer Res       Date:  2018-01-17       Impact factor: 12.701

4.  USP18 Sensitivity of Peptide Transporters PEPT1 and PEPT2.

Authors:  Jamshed Warsi; Zohreh Hosseinzadeh; Bernat Elvira; Lisann Pelzl; Ekaterina Shumilina; Dong-Er Zhang; Karl S Lang; Philipp A Lang; Florian Lang
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

5.  High expression of USP18 is associated with the growth of colorectal carcinoma.

Authors:  Lin Zhang; Ningning Zhang; Xin Li; Wanxin Wu; Yanping Zhang; Jingyu Wang
Journal:  Histol Histopathol       Date:  2021-05-27       Impact factor: 2.303

6.  USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.

Authors:  Bangxing Hong; Haiyan Li; Yong Lu; Mingjun Zhang; Yuhuan Zheng; Jianfei Qian; Qing Yi
Journal:  Mol Cancer       Date:  2014-05-31       Impact factor: 27.401

7.  Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.

Authors:  Haowen Xiao; Li-Mengmeng Wang; Yi Luo; Xiaoyu Lai; Caihua Li; Jimin Shi; Yamin Tan; Shan Fu; Yebo Wang; Ni Zhu; Jingsong He; Weiyan Zheng; Xiaohong Yu; Zhen Cai; He Huang
Journal:  Oncotarget       Date:  2016-01-19

8.  Suppression of USP18 Potentiates the Anti-HBV Activity of Interferon Alpha in HepG2.2.15 Cells via JAK/STAT Signaling.

Authors:  Lin Li; Qing-Song Lei; Shu-Jun Zhang; Ling-Na Kong; Bo Qin
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  miR-139 modulates MCPIP1/IL-6 expression and induces apoptosis in human OA chondrocytes.

Authors:  Mohammad Shahidul Makki; Tariq M Haqqi
Journal:  Exp Mol Med       Date:  2015-10-09       Impact factor: 8.718

10.  Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.

Authors:  Fadzai Chinyengetere; David J Sekula; Yun Lu; Andrew J Giustini; Aarti Sanglikar; Masanori Kawakami; Tian Ma; Sandra S Burkett; Burton L Eisenberg; Wendy A Wells; Paul J Hoopes; Elizabeth G Demicco; Alexander J Lazar; Keila E Torres; Vincent Memoli; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.